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Failures of radical radiotherapy
in patients with non-small cell lung cancer
El˝bieta Chmielewska1, Wojciech Michalski2
Introduction. Lung cancer is the most frequent malignant neoplasm in man. In Poland the morbidity indicators for lung
cancer are larger than the world average. The yearly increase of this factor in men in Poland is twice that in any other
European country. The basic method of treatment of non-small cell lung cancer is surgery, however, under Polish con-
ditions, only about 15% of patients qualify for it. Therefore, still a large group of patients become potential candidates for ra-
diotherapy. In the early period, radiotherapy had mainly a palliative character. The possibilities of radical treatment emerged
in the fifties, together with the application of megavoltage apparata. However, five-year survivals do not surpass the level of
6–10%. Therefore, analyses of the results of radical radiotherapy are carried out in order to find the reasons of its failures, as
this implies the direction of search for improving the efficiency of the therapy.
The aim of the study. The aim of the study was to assess the failures of radical radiotherapy in patients with non-opera-
ble, non-small cell lung cancer. The results obtained will be the basis for revision and rationalisation of the present indications
to radical radiotherapy in patients with non-small cell lung cancer.
Material. Between January 1, 1990, and December 31, 1995, 2330 patients with non-small cell lung cancer attended the Out-
patient Clinic of the The Maria Sklodowska Curie Memorial Cancer Center in Warsaw. Basing on the results of clinical exa-
mination and additional analyses, 260 patients qualified for radical radiotherapy (31 women (12%) and 229 men (88%)).
In a majority of cases the stage of the disease was advanced: stage IIIA was found in 114 patients (44%), and stage IIIB in
73 patients (28%).
Methods . The survival time and the time to local progression were the basis for the analysis. The survival probability was cal-
culated with the Kaplan-Meier method. As a failure of treatment the first information on progression, local or distant, was as-
sumed. The frequency of failure in the first and the second year of observation was compared. To this end, the McNemar test
for related observations was used.
Results. Survival probability at two years was 32±2 % and at five years 10%±2%. Two-year local control was observed in
16%±2% and five-year in 6±2 % of cases.
In the two-year observation local recurrence was the more frequently observed failure (p=0.002) (113 cases), than the distant
metastases (47 cases).
Conclusions. 1. Loco-regional failure of cancer control is the main failure of treatment in radical radiotherapy of patients
with non-operable, non-small-cell lung cancer. 2. The majority of failures emerges in the first two years of observation. More
frequently this is local recurrence (p=0.002). 3. Radical radiotherapy with total doses of 60-70 Gy in patients with non-ope-
rable, non-small-cell lung cancer allows to obtain two-year survivals in 33±2 % of cases, and two-year survivals without symp-
toms of the disease in 16±2 % of cases.
Analiza niepowodzeƒ radykalnej radioterapii
u chorych na niedrobnokomórkowego raka p∏uca
Wst´p. Rak p∏uca jest najcz´stszym nowotworem z∏oÊliwym u cz∏owieka. W Polsce wskaêniki zachorowalnoÊci na raka p∏u-
ca kszta∏tujà si´ powy˝ej Êredniej Êwiatowej. Roczne tempo wzrostu wspó∏czynnika umieralnoÊci na raka p∏uca u m´˝czyzn
w Polsce jest w ostatnim dwudziestoleciu dwukrotnie szybsze ni˝ w jakimkolwiek innym kraju Europy. Podstawowà metodà
leczenia niedrobnokomórkowego raka p∏uca jest zabieg chirurgiczny, jednak w warunkach polskich mo˝e byç do niego zakwa-
lifikowanych tylko oko∏o 15% chorych. Z tych przyczyn ciàgle du˝a grupa chorych staje si´ potencjalnymi kandydatami do ra-
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Introduction
Lung cancer is the most frequent malignant neoplasm in
man. For the last 20 years it has been the most frequent
malignant neoplasm in Polish men and is now it the third
found in Polish women [1-3]. In the United States it holds
the second place among malignant neoplasms (preceded
by prostate cancer in men and breast cancer in wo-
men) [4]. The morbidity indicators for lung cancer in Po-
land surpass the world average [2]. In the last two deca-
des, the yearly increase of this factor in men in Poland is
twice that in any other European country [2].
One of the established methods of treatment of non-
-small cell lung cancer is radiotherapy. In the early period,
radiotherapy had mainly a palliative character [5]. The
possibilities of radical treatment emerged in the fifties, to-
gether with the application of megavoltage apparata. Ho-
wever, five-year survivals do not exceed 6-10% [6-8]. Such
results stem form quick local recurrences, as well as from
distant metastases [9-15]. Therefore, analyses of the re-
sults of radical radiotherapy are carried out in order to
find the reasons of its failures, as this implies the direction
of research for improving the efficiency of the therapy.
The aim of the study
The aim of the study was to assess the failures of radical
radiotherapy in patients with non-operable, non-small
cell lung cancer. The earliest information on progres-
sion, local or distant, was considered failure of treat-
ment. The results thus obtained constituted the basis for
revision of the present indications for radical radiothera-
py in patients with non-small cell lung cancer and ratio-
nalisation of the follow-up system in this group of pa-
tients.
Material
Between January 1, 1990 and December 31, 1995, 2330 patients
with non-small cell lung cancer attended the Otpatient Clinic of
the Maria Sklodowska-Curie Memorial Cancer Center in War-
saw. After clinical and additional examination 260 patients quali-
fied for radical radiotherapy. The group constituted of 31 women
(11.9%) and 229 men (88.1%), aged between 24 and 79 (mean
61, median 62).
Clinical stage was assessed according to TNM classification.
In the considered group there were 16 patients (6.2%) in stage
I and 57 (21.9%) in stage II of the disease. In a majority of cases
the neoplastic process was considerably advanced: stage
III A was found in 114 patients (43,8%) and stage III B in 73 pa-
tients (28,1%).
Blood count and chemistries were analysed in all the ca-
ses. In 200 patients chest tomography was performed to as-
sess tumour size, in 47 other patients the information on the si-
ze of the lesion was obtained during exploratory thoracoto-
my. In the remaining patients the tumour size was estimated
from the chest X-rays. The largest transversal dimension of
the tumour was between 10 mm and 90 mm (mean 54 mm,
median 50 mm).
dioterapii. W poczàtkowym okresie mia∏a ona g∏ównie charakter paliatywny. Mo˝liwoÊci leczenia radykalnego pojawi∏y si´ w la-
tach 50. wraz z zastosowaniem aparatów megawoltowych. Prze˝ycia pi´cioletnie nie przekraczajà jednak 6–10%. W takiej sy-
tuacji prowadzone sà analizy wyników radykalnej radioterapii celem ustalenia jej niepowodzeƒ, poniewa˝ implikuje to kieru-
nek poszukiwaƒ zwi´kszania skutecznoÊci terapii.
Cel  pracy. Celem pracy by∏a ocena niepowodzeƒ radykalnej radioterapii u chorych na nieoperacyjnego, niedrobnoko-
mórkowego raka p∏uca. Uzyskane wyniki b´dà podstawà do zrewidowania i zracjonalizowania dotychczasowych wskazaƒ do
radykalnej radioterapii u chorych na niedrobnokomórkowego raka p∏uca.
Materia∏. W okresie od 1 stycznia 1990 r. do 31 grudnia 1995 r. do Ambulatorium Centrum Onkologii-Insytutu na Ursyno-
wie zg∏osi∏o si´ 2330 chorych na niedrobnokomórkowego raka p∏uca. Na podstawie badania klinicznego i badaƒ dodatkowych,
do radykalnego leczenia napromienianiem zakwalifikowano 260 chorych. W powy˝szej grupie znajdowa∏o si´ 31 kobiet
(12%) i 229 m´˝czyzn (88%). W wi´kszoÊci przypadków stwierdzano znaczne zaawansowanie procesu nowotworowego: sto-
pieƒ IIIA ustalono u 114 chorych (44%), a stopieƒ IIIB u 73 chorych (28%).
Metody . Podstawà do oceny niepowodzeƒ by∏ czas prze˝ycia oraz czas prze˝ycia bez progresji choroby. Prawdopodobieƒstwo
prze˝ycia i prze˝ycia wolnego od choroby obliczano metodà Kaplana-Meiera [17]. Jako niepowodzenie leczenia przyj´to pierw-
szà informacj´ o progresji, lokalnej lub odleg∏ej. Porównano cz´stoÊç wyst´powania niepowodzenia leczenia w pierwszym i dru-
gim roku obserwacji. Do tego celu u˝yto testu dla obserwacji powiàzanych McNemar’a.
Wyniki . Dwuletnie prze˝ycie w ca∏ej grupie chorych wynios∏o 33±2 %, a pi´cioletnie 10±2 %. Dwuletnie prze˝ycie bez cech
choroby wynios∏o 16±2 %, a pi´cioletnie 6±2 %.
W dwuletniej obserwacji cz´Êciej obserwowanym niepowodzeniem by∏ miejscowy nawrót choroby (p=0,002), który mia∏
miejsce w 113 przypadkach, ni˝ przerzuty odleg∏e, które odnotowano w 47 przypadkach.
Wnioski . 1. Niewyleczenie loko-regionalne raka jest zasadniczym niepowodzeniem radykalnej radioterapii chorych na
nieoperacyjnego, niedrobnokomórkowego raka p∏uca. 2. Wi´kszoÊç niepowodzeƒ leczenia pojawia si´ w ciàgu pierw-
szych dwóch lat obserwacji. Cz´Êciej (p=0,002) jest to nawrót miejscowy. 3. Radykalna radioterapia z zastosowaniem ca∏-
kowitych dawek promieniowania 60-70 Gy u chorych na nieoperacyjnego, niedrobnokomórkowego raka p∏uca, pozwala uzy-
skaç dwuletnie prze˝ycie w 33±2 % przypadków, a prawdopodobieƒstwo dwuletniego prze˝ycia bez cech choroby wyno-
si 16±2 %.
Key words: radical radiotherapy, failure, non-small cell lung cancer
S∏owa kluczowe: radykalna radioterapia, niepowodzenia, niedrobnokomórkowy rak p∏uca
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C l i n i c a l  c h a r a c t e r i s t i c s
The overall performance status score was assessed according
to Zubrod. There were 19 patients with score 0 (7.3%), 216
with score 1 (83%) and 25 with score 2 (9.6%).
Weight loss during the last six months before treatment
was reported by 98 patients (37.7%). Losses between 1 kg to
20 kg (mean 2,25 kg). In 67 patients (25.8%) weight loss of at le-
ast 5 kg was observed. Of the 260 patients, in 47 (18%) explora-
tory thoracotomy was performed before irradiation. All these in-
terventions were performed outside our Cancer Center. In a ma-
jority of patients surgeons performed pulmonary function tests.
Sixty three patients disqualified from the surgery as they revealed
the features of dyspnoea. More detailed information on the as-
sessed group of patients had been presented in our previous
paper [16].
M e t h o d  o f  t r e a t m e n t
The patients who qualified for radical irradiation treatment pre-
sented the following characteristics: good overall state, no si-
gnificant dyspnoea (easily climbs two flights of stairs), no severe
circulatory insufficiency resistant to treatment, weight loss not
exceeding 10% during last six months, disease with local advan-
cement, no involvement of the supraclavicular lymph nodes, no
oesophagus infiltration and no infiltration of the entire wall of
the myocardium, the chest wall and the spine (excluding the
Pancoast tumour), no presence of neoplasmatic cells in the pleu-
ral or pericardial cavity liquid. The basic qualification criterion
was the tumour size. Patients with the transversal dimension of
the tumour not exceeding 6-7 cm were treated.
The irradiation treatment was carried out according to
a uniform treatment protocol, under the supervision of the sa-
me group of physicians. The treatment was carried out in two
stages. In the first stage a 44-46 Gy dose was administered to the
tumour site with the neighbouring mediastinum using the AP
fields. In the second stage the dose tothe tumour was incre-
ased up to 64-69 Gy, with the use of oblique fields, while avo-
iding the spinal cord. The technique of large fields, i.e., fields in-
cluding the tumour and the neighbouring mediastinum region
was applied to 234 patients. A 2 cm margin of normal tissue aro-
und the tumour and the involved mediastinum lymph nodes
was added. The mediastinum of the normal side was surrounded
by a 1 cm margin on the left in the case of the right lung tumo-
ur and a 2 cm margin on the right in the case of the tumour in
the left lung. In nine cases the supraclavicular region on the
side of the tumour was included, due to the tumour of lung
top. In 26 patients (10%) the treatment was carried out with
small fields including the tumour and the nearest lymph no-
des. This was the group in which the overall state or the impa-
ired pulmonary function created a risk of severe complications.
For all the patients the total dose was calculated according to
the ICRU recommendations in the middle of the AP dimension
in the central radius for the AP fields and in the isocentre for
the oblique fields.
Conventional irradiation, 2 Gy per day, 5 times per week
was applied to 254 patients. Also 6 patients in whose cases the
first stage of treatment was carried out with non-conventional
fractionation were included in the analysis. This was the group
initially qualified for palliative therapy. In this group after the
first stage of treatment significant tumour regression was obse-
rved in the computer tomography tests and the qualification
was altered from palliative to radical. The equivalent dose for the
first stage of treatment was recalculated with the linear-quadra-
tic formula.
Irradiation was carried out with the Cobalt 60 gamma be-
ams or photon X beams with energies of 4, 9 and 15 MeV obta-
ined in linear accelerators. In the cases where the first stage of
treatment was performed with Cobalt or photons of 4 MeV, the
second stage was carried out with higher energy.
Fo l l o w - u p  e x a m i n a t i o n s
After the treatment was completed the patients were obliged
to present themselves for a follow-up examination every three
months, if the clinical stage did not imply the necessity for more
frequent examinations. During each examination a chest X-ray
was made. Each six months an ultrasound examination of the ab-
dominal cavity and basic blood tests were carried out. Other
diagnostic tests were made according to individual requirements.
In the case of absence of a patient for longer than six months,
either he was called upon by telegraph, or his doctor or family
were contacted.
S t a t i s t i c a l  m e t h o d s
The source for the retrospective analysis of the clinical material
were the case histories. The observation was closed on Decem-
ber 31, 1997. For all the patients information whether they were
alive, or, in case of the contrary, the date of death was establi-
shed. The material comprised information on 260 patients.
The basic information for the assessment of results was
the survival time and the time to local progression. Local pro-
gression was assessed from the chest X-ray. The survival time
was measured from the starting date of irradiation to the date of
death or the date of the last information that the patient lives. Ti-
me to local progression was measured from the starting date of
irradiation to the date of finding the features of progression or,
if the progression was not found, the date of the last clinical
examination. Bronchoscopy for confirming the restoration was
not carried out in any case. Survival probability and disease-
-free survival probability was calculated with The Kaplan-Meier
method [17]. As the failure of treatment the first information on
progression, local or distant, was assumed. The frequency of fa-
ilure in the first and the second year of observation was compa-
red. To this end, the McNemar test for combined related obse-
rvations was used. Neither observation was shorter than two
years. For 64 patients a detailed reason of death was not known
(in the last clinical examination carried out at the Center of
Oncology no features of illness were found).
Results
The time of observation varied between 2 and 98 months,
median 16 months. Two-year survival in the entire group
of patients was 33±2 % and five-year survival was
10±2 %. Two-year survival without symptoms of the dise-
ase was 16±2 %, and five-year survival was 6±2 %. The
results obtained are shown in Tab. I and Figs. 1 and 2. In
the two-year observation the more frequently observed
failure was local recurrence of the disease, present in
113 cases (p=0.002), and distant metastases, found in
47 cases, were less frequent. In the second year of obse-
rvation the symptoms of local recurrence were found in
Tab. I. Survival probability and probability of survival 
without the symptoms of the disease
in the analysed group of 260 patients, with a 95% confidence interval
Time of observation Survival probability Probability of survival 
(months) (95% CI) without the symptoms 
of the disease (95% CI)
12 0.60 (0.540.66) 0.40 (0.340.46)
24 0.33 (0.290.37) 0.16 (0.120.20)
60 0.10 (0.060.14) 0.06 (0.020.10)
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84% of the patients. The probability of survival without
local recurrence between the third and fifth year of obse-
rvation stayed at a nearly constant level – after 36 months
it was 27% and after 60 months – 24%. The probability
of survival without distant metastases remained at a ne-
arly constant level during the entire period of observa-
tion. It was 88% after six months, 78% after 12 months,
63% after 24 months, and remained constant after 36
and 60 months, equalling 59%. In the analysed material
during the two-year observation in five patients local re-
currence and distant metastases occurred simultaneously.
These cases were assigned to the category of local re-
currences. This is the “pessimistic” option for the exami-
ned material. During the entire observation the symp-
toms of local recurrence and distant metastases appe-
ared in 46 patients (17.7%). In this case the time factor is
not taken into consideration, hence, its interpretation
is doubtful.
Among the 64 patients who had died without the
symptoms of the disease, in 15 cases the cause of death
was determined. In nine patients the direct cause of death
was infarctus, in one – apoplectic stroke without symp-
toms suggesting metastases (the patient had no computed
tomography and the diagnosis was established basing
upon neurological examination), in two patients – car ac-
cident, in two – suicide, in one – haemorrhage from
gastric ulcer. In this group correspondence contact was es-
tablished with all the families of the patients or their gene-
ral practitioner doctors. In some ten to twenty cases infor-
mation on the recurrence, either local or distant, was re-
ceived, but without a precise date of this event.
Consequently, these patients could not be included in
any significant analysis.
Discussion
In the present study an assessment of failures of radical
radiotherapy applied as the sole method of treatment in
260 patients with non-operable, non-small-cell lung can-
cer was carried out. The analysis has a retrospective cha-
racter, it therefore bears all the limitations of such a me-
thod: difficulties in a comparative analysis with other pu-
blished experiments, limited credibility of information
contained in the case histories due to subjectivity of inter-
pretations, and lack of full information on the group of
patients not qualified to the treatment.
In Tab. II the own results are confronted with those
obtained elsewhere in patients treated with comparable
methods. The analysis of these results does not lead to
optimistic conclusions. Local efficiency is poor, two-year
survivals reach the level of 20% [6, 10, 18], and in a vast
majority of cases five-year survivals do not exceed 10%
Fig. 1. Survival in the group of 260 patients with the non-small cell
lung cancer, treated with the radiotherapy alone as a radical treat-
ment
Fig. 2. Survival without progression of the disease in the group of 260
patients with the non-small cell lung cancer, treated with the radiothe-
rapy alone as a radical treatment
Tab. II. Comparison of the results of radical radiotherapy of the non-small-cell lung cancer
Author Number of 2-year 2-year local 5-year 5-year local
patients survival control survival control
Perez [27] 105 19.0% – – –
Katz [18] 115 17.0% – 6% –
Johnson [16] 106 12.5% – 3% –
Durci [9] 81 24.0% 28% 9% 15%
Morton [26] 58 16.0% 15% 7% –
Hazuka [13] 88 37.0% 44% – –
Koukourakis [19] 153 25.0% 19% 13% 10%
Wigren [36] 134 14.8% – – –
Chmielewska 260 33.0% 35% 10% 23%
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[6-8, 18]. For a radiotherapist the results of local control
after radiotherapy are frustrating, as in the majority of pu-
blished papers it oscillates between slightly above ten and
30% after two years, and after five years attains merely
10-15%. The basic failure of treatment is local recurren-
ce, observed in nearly 80% of patients. Blood-related
dissemination is found in around 75% of patients [7, 9-15,
19].
The attempts to improve local control consisted of
increasing the total dose, applying non-conventional frac-
tionation methods and using combined treatment: che-
mo-radiotherapy. Higher percentages of local control
were received with the increase of the administered total
dose, conventionally fractionated [1, 10, 13, 20, 21] and
non-conventionally fractionated [22-28]. A clear dose-
-effect relation was demonstrated by many authors. Ha-
zuka observed higher percentages of full regression for
total doses larger than 67.6 Gy (p=0.018) [10], and Mar-
tel for doses larger than 70 Gy (p=0.055) [29]. A similar
relation between the total dose and the result of treat-
ment was demonstrated by Soresi and Ansari, who achie-
ved 15% and 20% of two-year survivals with conventio-
nally fractionated doses of 50 Gy and 60 Gy, respective-
ly, in combined treatment with cisplatin [30, 31].
Investigations on the application of non-conventio-
nal fractionation gave an improvement of overall survi-
vals. In the studies by Brindle [26], Byhard [23] and
Cox [24] the two-year survivals were between 21 and
29%. Definitely the most interesting results were publi-
shed by Saunders [27]. In a group of 62 patients irradia-
ted with the CHART technique (Continous, Hyperfrac-
tionated, Accelerated Radiotherapy: 3 fractions of 1.5 Gy
daily, with a break of 6 hours, during subsequent 12 days;
total dose 54 Gy) she observed that the probability of
a one-year survival equal to 64%, and that of a two-year
survival equal to 34%. The results of combined treat-
ment, and especially the concurrent radio-chemotherapy,
focused the research in a new direction. Five-year ob-
servations, and longer, demonstrated a statistically si-
gnificant difference of survivals in favour of the combined
treatment (p=0.02), and also a statistically significant
decrease of distant metastases (p=0.002) [7, 12, 14].
The performed analysis demonstrated that the basic
reason of failure of the treatment was local recurrence of
cancer, while distant metastases emerged in a considera-
bly smaller number of the patients. Therefore the trials
aimed principally at improving local results seem impor-
tant. These can be carried out either in the way of further
improvement of the biological value of the administe-
red dose, or by combining radiotherapy with such cytosta-
tics which have a radiosensitizing action or suppress the
repair of post-irradiation damages in cancer cells. The
following drugs belong to this group: cisplatin, docetaxel,
winorelbine and gemcytabine. The results of the perfor-
med analysis seem to imply that in a selected group of
patients it is advisable to increase the total irradiation do-
ses, even to 76-80 Gy, in combination with a full repetiti-
veness of a three-dimensional therapy plan, providing
for sparing normal anatomical structures. The authors of
many studies indicate that shortening the total irradiation
time improves local control and long-term results of the
treatment in a significant way [32-34].
The unsatisfactory results of treatment of patients
with non-small cell lung cancer remain a constant challen-
ge to oncologists and constitute an incentive for a future
search of more efficient therapeutic methods.
Conclusions
1. Loco-regional failure of cancer therapy is the principal
failure of radical radiotherapy in patients with non-
-operable, non-small-cell lung cancer.
2. The majority of failures of the therapy emerge during
the first two years of observation. Local recurrence is
more frequent (p=0.002) than distant metastases.
3. Radical radiotherapy with total doses of 60-70 Gy in
patients with non-operable, non-small-cell lung can-
cer allows to achieve two-year survivals in 33±2 % of
cases, and the probablility of a two-year survival witho-
ut the symptoms of the disease is 16±2 %.
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